2023
Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2022
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group
Dicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group. Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildFemaleFrozen SectionsHumansNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsParaffinRetrospective StudiesTesticular NeoplasmsConceptsIntra-operative frozen sectionOvarian germ cell tumorsGerm cell tumorsMalignant ovarian germ cell tumorsIntra-operative frozen section diagnosisFrozen section diagnosisCentral pathology reviewCell tumorsSurgical stagingAdolescent patientsFinal diagnosisFinal paraffin section diagnosisSection diagnosisFrozen sectionsParaffin section diagnosisOncology GroupPathology reviewCentral reviewOvarian germ cell malignanciesNonseminomatous germ cell tumorsGerm cell tumor componentsConfirmation of malignancyGerm cell malignanciesRecords of patientsChildren's Oncology Group
2021
Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors
Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.Peer-Reviewed Original ResearchConceptsHazard of deathCentral nervous system tumorsNervous system tumorsRace/ethnicitySocioeconomic statusSystem tumorsMultivariate Cox proportional hazards modelNon-Hispanic black patientsNon-Hispanic white patientsPrimary central nervous system tumorsCox proportional hazards modelEnd Results (SEER) databaseRetrospective cohort studyPrimary CNS tumorsYoung adult patientsNeuro-oncology patientsProportional hazards modelLowest SES tertileLow socioeconomic statusNHB patientsAYA patientsHazard ratioNHW patientsAdult patientsCohort study
2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolDiagnostic ImagingFemaleHumansInfantNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsRetrospective StudiesTeratomaConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trialPatterns of medication use at end of life by pediatric inpatients with cancer
Prozora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. Patterns of medication use at end of life by pediatric inpatients with cancer. Pediatric Blood & Cancer 2020, 68: e28837. PMID: 33306281, DOI: 10.1002/pbc.28837.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornInpatientsMaleNeoplasmsPalliative CareRetrospective StudiesTerminal CareYoung AdultConceptsMedication usePediatric inpatientsVizient Clinical Database/Resource ManagerHematopoietic stem cell transplantLife-sustaining medicationsMedication utilization patternsSymptom management medicationsUse of opioidsStem cell transplantIntensive care unitLength of stayAcademic medical centerResource use dataLast weekWarrants further studyEvidence-based approachVasopressor useEnd of lifeCare unitCell transplantMedication categoriesResuscitate statusRetrospective studyMalignancy typeOdds ratioOutcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium
Shaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolHumansInfantInfant, NewbornLymphatic MetastasisMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalProgression-Free SurvivalRetroperitoneal NeoplasmsRetrospective StudiesTesticular NeoplasmsYoung AdultConceptsMetastatic germ cell tumorsEvent-free survivalGerm cell tumorsCell tumorsRisk groupsYoung adultsAge groupsMale patientsAdolescent patientsAdolescent malesCox proportional hazards analysisMalignant germ cell tumorsIndividual patient databasePlatinum-based chemotherapyProportional hazards analysisYoung adult patientsClinical trial organizationsAdolescent age groupPediatric cooperative groupsTreatment of adolescentsDifferent age groupsAdult patientsClinical characteristicsEFS rateInclusion criteriaRe: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
Pashankar F, Frazier AL. Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. European Journal Of Cancer 2020, 130: 265-266. PMID: 32178968, DOI: 10.1016/j.ejca.2020.01.022.Peer-Reviewed Original Research
2019
α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensification
2018
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group
Fonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group. Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.Peer-Reviewed Original ResearchConceptsMalignant germ cell tumorsTumor marker elevationNongerminomatous malignant germ cell tumorsAbnormal tumor markersGerm cell tumorsMarker elevationTumor markersRelapse surveillanceOncology GroupInitial diagnosisCell tumorsChildren's Oncology GroupDetection of relapseSingle-arm trialNormal tumor markersCase report formsAbnormal imagingCentral reviewMarker levelsPathology reportsRelapsePatientsPhase IIIReport formsComplete data
2014
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAlpha-FetoproteinsBiomarkers, TumorChildChild, PreschoolClinical Trials as TopicDisease-Free SurvivalEndodermal Sinus TumorEvidence-Based MedicineFemaleHumansMaleModels, StatisticalNeoplasm StagingNeoplasms, Germ Cell and EmbryonalPredictive Value of TestsPrognosisRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomUnited StatesConceptsGerm cell tumorsYolk sac tumorPediatric germ cell tumorsClinical trial dataAlpha-fetoproteinTumor siteOncology GroupCell tumorsMalignant pediatric germ cell tumorsPediatric extracranial germ cell tumorLong-term disease-free survivalEvidence-based risk stratificationExtracranial germ cell tumorsTrial dataPure yolk sac tumorPoor-risk groupStage IV diseaseDisease-free survivalPercentage of patientsChildren's Oncology GroupElevated alpha-fetoproteinPlatinum-based therapyClinical trial organizationsParametric cure modelsLeukemia group
2013
Weight Status of Children With Sickle Cell Disease
Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight Status of Children With Sickle Cell Disease. Pediatrics 2013, 131: e1168-e1173. PMID: 23460681, DOI: 10.1542/peds.2012-2225.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBaseline Hb levelsHb levelsBMI percentileWeight statusCell diseaseHigher baseline Hb levelsSCD-related complicationsRetrospective chart reviewObesity-related conditionsOverweight/obesityRecent clinic visitYears of ageCalendar year 2007Select comorbiditiesChart reviewClinic visitsDL increaseElevated BMIHemoglobin levelsObese statusSickle genotypeUnderweight individualsHb SSDemographic information